AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback